About Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment.
Quality Assessment
Assembly Biosciences, Inc. is a high-risk healthcare company with a Compass Score of 10. Poor quality metrics and high risk. Not one for conservative investors.
Score Breakdown
The Compass Score is based on 6 quality factors identified by academic research.
Click any factor to see detailed metrics
Valuation Metrics
Click any metric for details
Wall Street View
Catalyst Signal
PlusRecent earnings beats and analyst-upgrade momentum. How it works
Analyst Track Record
Financial Health
PlusClick any metric for details
Growth Projections
PlusTechnical Overview
Click any metric for details
Similar High-Quality Stocks
Important Disclaimer
The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.
Unlock Detailed Metrics
Upgrade to Plus to see the actual financial values behind each quality factor.
- See exact ROA, cash flow ratios, and more
- Unlimited stock views + smart search
- Export data to CSV
- Golden Stocks + analyst coverage
Cancel anytime